16.1 Delirium vs Dementia, Alcohol Withdrawal Syndromes, Delirium Tremens, and Wernicke-Korsakoff

Key Takeaways

  • Delirium is a recent and often fluctuating change in attention or awareness. Check baseline and use the appropriate assessment tool, then identify and treat causes.

  • Use de-escalation and address reversible needs. Consider short-term medication only when risk or distress warrants it. Haloperidol is contraindicated in Parkinson disease and dementia with Lewy bodies.

  • Distinguish dementia subtypes through history, examination, function and targeted testing. Individualise medicines and supports with the patient and carers.

  • Alcohol withdrawal delirium needs urgent monitored treatment and parallel assessment for other causes. CIWA-Ar relies on patient responses and should not guide treatment in delirium.

  • Treat symptomatic hypoglycaemia immediately and give parenteral thiamine promptly for suspected Wernicke encephalopathy. For inpatient opioid substitution, verify recent doses and plan handover to the community team.

Last updated: November 2026

Distinguishing Delirium, Dementia and Depression

Acute change over hours or days in attention, awareness or other cognition suggests delirium. Compare with the patient's baseline using observations, notes and collateral history. Look for fluctuation and reduced alertness as well as agitation. A person with dementia can develop delirium in hospital. When both are plausible, assess and manage delirium first.

FindingDeliriumDementiaDepression with cognitive symptoms
Time courseRecent change over hours to days, often fluctuating.Decline over months or longer, with patterns depending on cause. Lewy body dementia can fluctuate, and vascular decline may be stepwise.Cognitive and mood symptoms often develop together over weeks or longer.
Attention and alertnessInattention is prominent. The patient may be drowsy, unusually alert or apparently alert at one encounter.May be relatively preserved early in some subtypes. Fluctuating alertness may be a clue to Lewy body disease.Poor concentration or slowed thinking can occur. Check other causes if alertness is altered.
History and functioningA nurse or relative notices a change, such as new disorientation, inability to follow conversation or altered sleep.Reported decline interferes with previously independent daily tasks, such as managing money or medications.Ask about mood, loss of interest, sleep, energy and thoughts of self-harm. Concentration and memory may improve with treatment, but persistent difficulties need reassessment.

Worked distinction. A person usually able to converse is quiet after surgery and loses track of questions, with more confusion in the evening. Assess a change in attention and alertness, check observations and medicines, and investigate likely physiological causes. Baseline memory problems increase vulnerability and do not explain away the acute change.

Recognise Delirium and Investigate Its Cause

Hyperactive delirium may cause agitation and pulling at lines. Hypoactive delirium may cause withdrawal, fewer responses or reduced movement and can be easy to miss. The mixed presentation includes periods of both. Ask about the patient's baseline, acute change, sleep, food and fluid intake, mobility, continence and recent medicines or substances. Assess circulation, breathing, oxygenation, bedside glucose and other observations promptly when indicated.

Potential precipitantFocused assessment
Pain, urinary retention or constipationLook for recent injury, surgical pain, poor bladder emptying or an altered bowel pattern. Examine and use bladder scanning or further tests when the findings indicate.
InfectionAssess for localising signs and possible sepsis. HSE guidance advises against urine dipsticks to diagnose UTI in people aged 65 and over or with a catheter. Confusion alone does not establish UTI. If urinary infection is suspected, follow the relevant clinical and sampling pathway.
Dehydration, malnutrition, hypoxia or poor perfusionAssess intake, fluid status and vital signs and treat urgent physiological deficits. Consider thiamine deficiency with malnutrition and alcohol dependence.
Medicines or substance withdrawalReview recent dose changes, anticholinergics, sedatives, opioids and possible alcohol or sedative withdrawal.
Metabolic, endocrine, neurological or environmental causeSelect tests based on the findings, including glucose, electrolytes, organ function and assessment for focal neurological signs. Review sensory aids, an unfamiliar environment and disrupted sleep.

This checklist can organise the search for multiple contributors. Red flags such as a focal deficit, seizure or unexplained reduced consciousness may need urgent specific investigation.

Bedside assessment

The HSE adult acute pathways use 4AT. Score alertness (0 or 4), AMT4 orientation (0, 1 or 2), attention (0, 1 or 2) and an acute change or fluctuating course (0 or 4). AMT4 asks age, date of birth, place and current year. For months backwards from December, seven or more correctly scores 0, starts but gets fewer or refuses scores 1, and inability to start because of illness or inattention scores 2. Check recent acute change in the previous two weeks that is still evident in the last 24 hours.

A score of 4 or more suggests possible delirium, with or without cognitive impairment. A score of 1–3 suggests possible cognitive impairment, and a score of 0 makes delirium less likely at that moment. All require interpretation with the history and examination. Clinical assessment confirms the diagnosis. Under NICE CG103, use CAM-ICU or the Intensive Care Delirium Screening Checklist in critical care or postoperative recovery.

Worked 4AT. A person is alert (0), gets all AMT4 answers right (0), stops after four months backwards (1), and has a new fluctuation documented today (4). The total is 5. Assess for delirium and investigate causes even though orientation was intact. In the original ward Confusion Assessment Method, acute onset with fluctuation and inattention must accompany either disorganised thinking or altered consciousness.

Evidence-Based Management of Delirium: Environmental Reorientation and Restrained Pharmacotherapy

Delirium management requires a dual approach: vigorously treating the underlying organic causes identified via the PINCH ME workup while implementing comprehensive, multi-component non-pharmacological care. Use medication selectively for safety or severe distress while the team treats the cause.

Prevention and support during delirium

Use multicomponent care to prevent delirium and to support recovery during an episode:

  • Cognitive Reorientation: Maintain consistent, calm communication. Reintroduce staff by name and clinical role at every patient encounter. Position large, clearly visible analog clocks and updated daily calendars within the patient's direct line of sight. Place personal family photographs and familiar possessions on the bedside table.
  • Sensory Optimization: Ensure the patient's prescription spectacles are clean and worn during daylight hours. Verify that hearing aids are inserted, switched on, and fitted with working batteries. Address impacted cerumen.
  • Sleep-Wake Restoration: Maintain bright natural lighting during the day. Dim lights and reduce ward noise during the night. Consolidate nursing interventions, medication administration, and vital signs monitoring to avoid unnecessary nighttime awakenings.
  • Early Mobilization and Physical Activity: Encourage out-of-bed mobilization, chair sitting, and ambulation with physical therapy as clinically safe. Avoid unnecessary bed confinement.
  • Hydration, Nutrition, and Bowel Hygiene: Assist with regular oral fluids and meals; monitor intake-output charts. Prevent urinary retention and constipation through scheduled toileting and avoidance of unnecessary indwelling urethral catheters.

Medication for Severe Distress or Risk of Harm

Treat precipitating causes and use verbal and non-verbal de-escalation. If severe distress or serious risk persists, seek senior input. When haloperidol is suitable, use the lowest clinically appropriate dose for the shortest possible duration, with ECG and electrolyte assessment and review of QT-prolonging drugs. Check the route, dose and monitoring requirements in the applicable local policy and product information.

Haloperidol is contraindicated in Parkinson's disease, dementia with Lewy bodies and known QT prolongation. Dopamine blockade can worsen motor function and provoke severe neuroleptic reactions. If distress or danger persists in Parkinson's disease or dementia with Lewy bodies, seek urgent specialist advice about further management. Keep time-critical Parkinson medicines on schedule and seek specialist advice if the usual route cannot be used. Avoid routine benzodiazepines for general medical delirium. Alcohol or sedative withdrawal and end-of-life symptoms have separate protocols.

Dementia Assessment and Common Subtypes

Obtain a history of change and functional impact from the person and, with appropriate consent, someone who knows them. Review communication, medicines, mood, sleep, hearing, vision and other explanations. Perform a focused examination, validated cognitive assessment and appropriate blood tests. Refer for specialist or memory service assessment when cognitive decline remains unexplained. HSE integrates assessment and post-diagnostic support. In NICE NG97, structural imaging helps exclude other causes and determine subtype when appropriate. If the diagnosis is uncertain, select further testing where it will change management.

PatternFeatures that help distinguish itManagement implications
Alzheimer diseaseGradual progression, often with early episodic memory difficulties, then involvement of language, orientation or other functions. Medial temporal atrophy can support the assessment in context. Amyloid plaques and tau tangles are characteristic pathology.NICE recommends an acetylcholinesterase inhibitor such as donepezil, galantamine or rivastigmine for mild to moderate disease. Use memantine alone for moderate disease if an AChE inhibitor is contraindicated or intolerable, or for severe disease. Consider adding memantine to an AChE inhibitor in moderate disease and offer it in severe disease under that guideline.
Vascular cognitive impairment or dementiaSlowing and executive dysfunction, stroke history or focal signs. The course may be stepwise or gradual, with supportive vascular changes on imaging. Mixed pathology is possible.Address vascular risks and use secondary prevention when indicated by the underlying disease. Check stroke type and bleeding risk before antithrombotic decisions. NICE considers AChE inhibitors or memantine when there is suspected comorbid Alzheimer disease, Parkinson disease dementia or dementia with Lewy bodies.
Dementia with Lewy bodies (DLB)Fluctuating cognition, recurrent well-formed visual hallucinations, REM sleep behaviour disorder and spontaneous parkinsonism are core features. Dementia before or within a year of parkinsonism favours DLB over Parkinson disease dementia.Probable DLB can be supported by at least two core features or one with an indicative biomarker, such as reduced dopamine transporter uptake on appropriate SPECT. If medication is considered, NICE recommends donepezil or rivastigmine in mild to moderate DLB and permits memantine if AChE inhibitors are unsuitable. Avoid haloperidol because of severe neuroleptic sensitivity.
Frontotemporal dementiaBehavioural features may include early disinhibition, apathy, diminished empathy, compulsive behaviour, dietary change and executive dysfunction. Some patients present with progressive language problems, such as loss of word meaning or effortful, agrammatic speech.Provide support, speech and language input when relevant, and help for carers. NICE advises against AChE inhibitors and memantine for FTD. Seek specialist assessment for severe behavioural symptoms.

AChE inhibitors may cause gastrointestinal effects, weight loss, bradycardia and syncope. Check the pulse, cardiac history, related medicines and need for ECG under local guidance. Check renal function when using memantine. The Irish Donecept product starts at 5 mg daily for at least one month before considering 10 mg daily. Verify the formulation, dose and follow-up for the medicine selected.

Disease-modifying anti-amyloid therapies are restricted to specialist pathways and product-specific eligibility. EU lecanemab and donanemab authorisations specify early Alzheimer disease, confirmed amyloid pathology and no more than one copy of APOE ε4, with screening and monitoring for amyloid-related imaging abnormalities. EU marketing authorisation and Irish reimbursement are separate. In October 2026, NCPE recommended against reimbursement for lecanemab. Check current Irish commissioning and specialist pathways rather than assuming access.

Consider personal goals, medication safety, practical daily supports, future care planning and support for carers across subtypes. Assess consent and preferences for each decision.

Discuss driving when cognition changes

Ask about licence group, collisions or near misses, getting lost, visuospatial problems, attention, medication effects and what relatives have noticed, with appropriate permission. Under the Irish RSA 2026 guidance, dementia precludes Group 2 driving. Some people with early dementia may continue Group 1 driving after an appropriate assessment, with any licence restriction decided through the NDLS. Poor judgement, disorientation, declining function or evidence of unsafe driving requires prompt attention. Advise stopping if currently unsafe and help the driver meet notification requirements. If the person is considered fit to continue, the RSA advises review every six to twelve months or sooner if function changes, and a low threshold for formal on-road assessment. A cognitive screening score alone is insufficient. Discuss future transport options to support independence.

RSA Sláinte agus Tiomáint, updated August 2026, chapter 5 · RSA medical fitness and driver notification.

Recognising and Managing Alcohol Withdrawal

Withdrawal can occur after a major fall in alcohol intake in a dependent person. Ask about usual intake, the last drink, prior seizures or withdrawal delirium, current medicines, other substance use and physical illness. Reduced inhibitory activity and increased excitability after chronic exposure help explain tremor, autonomic activation and seizures.

PresentationCommon pattern and first decisions
Early withdrawalTremor, anxiety, sweating, nausea, insomnia and tachycardia often start within the first day. Assess severity, nutrition, medical illness and risk of complications.
HallucinationsHallucinations may occur while attention and orientation are relatively preserved. Marked inattention, disorientation or fluctuating alertness raises concern for withdrawal delirium or another medical cause.
Withdrawal seizureOften generalised within about two days of reduction. Stabilise the patient, check glucose and other causes, and treat according to the acute seizure and withdrawal pathways. Focal onset, head injury, prolonged seizures or an unusual timing warrants assessment for other causes.
Alcohol withdrawal delirium (delirium tremens)Usually occurs after two to four days, with delirium, tremor, sweating and other autonomic signs, sometimes hallucinations. Escalate urgently for monitored treatment and assess infection, injury, postoperative complications, medication effects and other causes in parallel.

The CIWA-Ar measures several symptoms including nausea, tremor, sweats, anxiety, sensory disturbance and orientation. Use scoring only as an adjunct in patients who can communicate reliably. The IAEM v1.1 guideline gives a symptom-triggered diazepam regimen for selected ED or clinical decision unit patients, with local admission criteria, observation and reassessment. The protocol excludes people with severe hepatic impairment, respiratory failure, major physical illness, haemodynamic instability or inability to communicate. Symptoms, prior complications and comorbid illness matter when deciding where and how to treat. Different protocols assign different thresholds.

Benzodiazepines reduce withdrawal symptoms and risk of seizures and delirium. Choose agent, route and dose according to clinical setting and severity, and monitor sedation and breathing. For significant liver impairment, specialist review can favour an agent with less reliance on hepatic oxidation, such as lorazepam. Respiratory failure requires urgent senior management and an airway plan.

In delirium, use a clinician-directed monitored withdrawal protocol. ASAM advises against CIWA-Ar in withdrawal delirium because symptom reporting is unreliable. Use appropriate objective monitoring, titrated benzodiazepines, assessment of perfusion and fluid needs, electrolyte correction when indicated, and prompt thiamine based on nutritional risk and symptoms. Escalate to critical care if severity, sedation or organ support require it. Arrange follow-up for alcohol dependence once the acute risk is controlled.

Recognise opioid dependence and keep treatment continuous

Ask about the pattern of use, craving, loss of control, withdrawal, overdose history and other substance use. Review physical and mental health and what the person wants from treatment. A drug test can support history and assessment. It cannot establish dependence or opioid tolerance by itself. Refer to the HSE addiction service or an appropriately trained and contracted GP when ongoing treatment is indicated. In the Irish opioid substitution treatment (OST) pathway, a Level 2 GP can assess and initiate treatment and a Level 1 GP can care for referred patients who are already stabilised. Methadone and buprenorphine-based medicines are treatment options within the pathway.

During admission: Ask which medicine the patient receives, when and how much they last took, and whether they have take-home doses. Independently verify the current prescription and last dispensing or administration with the community pharmacy or dispensing clinic and prescriber, using the Central Treatment List where appropriate. Check alertness, ventilation and additional sedatives. The confirmed usual regimen can generally continue if uninterrupted and clinically safe. After several missed days, tolerance may fall. Seek senior or addiction-team advice before restarting the usual dose, especially with methadone. If treatment cannot yet be confirmed, assess and manage withdrawal symptoms using the local pathway while seeking confirmation.

At discharge: Agree who will prescribe and dispense the next dose. Tell the community team whether that day's dose was given and how much. Discuss changes in tolerance and the risk of combining opioids with alcohol or sedatives. Offer access to take-home naloxone with training and an overdose rescue plan as appropriate. Acute respiratory depression needs emergency assessment and ventilatory support, with naloxone under the applicable emergency protocol.

HSE opioid substitution guideline · HSE hospital pathway summary · Irish College of GPs protocol · HSE take-home naloxone.

Assess substance use in a young person

Offer part of the consultation in private and explain the limits of confidentiality. Ask what was taken, how often and how recently, who supplies it, whether substances are combined, and what has changed at school or home. Assess for intoxication, poisoning, dependence or withdrawal, and ask separately about mood, psychotic symptoms, self-harm and safety. Severe intoxication, breathing problems or another immediate medical or psychiatric risk needs urgent care. Consider exploitation or neglect and apply Children First to any protection concern.

For a medically stable young person whose substance use is affecting function, agree immediate safety advice and a follow-up plan. Use the local HSE adolescent drug and alcohol pathway. When significant mental illness may coexist, arrange age-appropriate mental health assessment as well, using local CAMHS and addiction routes. The HSE dual diagnosis model provides specialist support to those teams when needed. Clarify which team will follow up during referral and involve a safe caregiver when appropriate to the young person's circumstances and consent.

HSE dual diagnosis model, chapter 13 · HSE CAMHS guideline · HSE advice on young people's alcohol or drug use.

Wernicke Encephalopathy and Korsakoff Syndrome

Thiamine supports glucose metabolism, including pyruvate dehydrogenase and transketolase activity. Deficiency may arise with poor intake or absorption, prolonged vomiting or severe alcohol dependence. Acute Wernicke encephalopathy is a clinical emergency. Look for confusion or change in alertness, unsteady gait or other cerebellar signs, and ocular signs such as nystagmus or ophthalmoplegia. Treat when suspected because the full triad may be absent.

Caine's operational criteria in people with chronic alcohol misuse use two or more of four features: dietary deficiency, eye signs, cerebellar dysfunction, and altered mental state or mild memory impairment. Do not wait for every classic feature before treating.

Treat suspected Wernicke encephalopathy and urgent hypoglycaemia

Give parenteral thiamine promptly when Wernicke encephalopathy is suspected. Check bedside glucose and treat clinically significant hypoglycaemia immediately, giving thiamine in parallel when feasible. Emergency glucose should not be delayed while thiamine is obtained. During ongoing nutrition or carbohydrate administration in a depleted patient, ensure early thiamine replacement. ASAM alcohol withdrawal guideline

Use the locally available IV thiamine preparation and hospital protocol. IAEM v1.1 uses two IV Pabrinex pairs three times daily for suspected Wernicke encephalopathy in its ED/CDU pathway when that product is used. The UK acute hospital guideline for suspected or established Wernicke encephalopathy uses 300–500 mg IV three times daily for three to five days with daily review, and advises further parenteral treatment when symptoms persist, followed by oral thiamine. Correct magnesium deficiency. In Ireland, one pair of Pabrinex IV consists of one No. 1 and one No. 2 ampoule and contains 250 mg thiamine. Two complete pairs provide 500 mg. Verify availability, dilution and infusion instructions with pharmacy, and use a monitored setting equipped to treat anaphylaxis. UK acute hospital alcohol guideline · HPRA Pabrinex SmPC

Korsakoff syndrome

Persistent difficulty forming new memories can follow Wernicke encephalopathy. Older memories may also be affected. A person may confidently fill memory gaps with accounts they believe, known as confabulation. Assess function, refer for specialist rehabilitation, support abstinence and nutrition, and arrange assistance suited to the person's needs. Recovery and care needs vary.

Loading diagram...
Clinical Algorithm: Staging and Emergency Management of Alcohol Withdrawal and Wernicke Encephalopathy
Test Your Knowledge

A 74-year-old man with Parkinson's disease becomes acutely confused and distressed by vivid hallucinations on the second day after hip fracture surgery. He has no new urinary symptoms or fever. His regular levodopa was delayed, and he has poorly controlled pain and palpable bladder distension. A clinician proposes intramuscular haloperidol. What is the safest immediate plan?

A

Avoid haloperidol, assess and treat reversible causes, restore time-critical Parkinson's therapy, and seek urgent senior or specialist advice if severe distress or risk persists.

B

Give intramuscular haloperidol immediately and review his pain and bladder only if agitation continues.

C

Stop levodopa and give high-dose intramuscular lorazepam routinely until his cognition recovers.

D

Start donepezil for the hallucinations and defer a medical assessment until the next day.

Test Your Knowledge

A 49-year-old man with a long-standing history of severe alcohol dependence is brought to the emergency department by ambulance after being found collapsed in a derelict building. On examination, he is disoriented to time and place, responds slowly to questions, and exhibits an unsteady, broad-based staggering gait. Cranial nerve examination reveals bilateral lateral rectus palsies and prominent horizontal nystagmus on lateral gaze. His capillary blood glucose is 2.9 mmol/L, heart rate is 104 beats/min, and blood pressure is 102/68 mmHg. What is the most critical immediate pharmacological sequence of interventions?

A

Administer 50 mL of 50% intravenous dextrose bolus immediately, followed by routine oral multivitamin tablets after 24 hours

B

Treat hypoglycaemia immediately with IV glucose and give parenteral thiamine promptly for suspected Wernicke encephalopathy.

C

Administer intravenous haloperidol 5 mg bolus to control confusion, followed by an intravenous normal saline infusion without thiamine

D

Administer oral chlordiazepoxide 100 mg immediately, withhold all intravenous fluids, and arrange an urgent CT scan of the brain prior to vitamin administration

Test Your Knowledge

A 52-year-old woman with alcohol dependence stopped drinking on admission for an operation. Three days later she is disoriented, tremulous and sweaty and reports insects crawling on her bed and arms. Her temperature is 38.8°C, heart rate 136 and blood pressure 182/108 mmHg. What is the most likely diagnosis and the best immediate management?

A

Acute surgical sepsis from bile peritonitis, requiring emergent exploratory laparotomy and broad-spectrum intravenous piperacillin-tazobactam

B

Severe postoperative opioid overdose, requiring continuous intravenous naloxone infusion and cessation of all analgesics

C

Alcohol withdrawal delirium. Escalate to monitored care for clinician-titrated benzodiazepines and investigate other causes of postoperative delirium in parallel

D

Alcoholic hallucinosis, requiring simple reassurance and oral paracetamol without benzodiazepine therapy

Test Your Knowledge

An adult admitted with cellulitis reports prescribed daily methadone and says the last dose was four days ago. He is alert, breathing normally and has early withdrawal symptoms. The dispensing pharmacy is open. What is the safest next step for his opioid treatment?

A

Give his reported usual full methadone dose now because withdrawal confirms his tolerance

B

Give naloxone to treat withdrawal before arranging discharge

C

Stop the existing treatment plan and defer all contact with addiction services until after discharge

D

Verify the prescription and last supply and seek senior or addiction-team advice before resuming methadone

Test Your Knowledge

A 16-year-old reports frequent cannabis use, missed school and episodes of hearing threatening voices even when sober. They are medically stable and can engage. What is the most appropriate initial plan?

A

Defer assessment of the voices until they can show weeks of abstinence

B

Assume primary schizophrenia and omit the substance assessment

C

Assess current safety, symptoms and substance use, and arrange coordinated adolescent mental health and addiction assessment

D

Refer directly to the adult addiction service and discharge without follow-up

Test Your Knowledge

A Group 1 driver with newly diagnosed dementia has become lost several times on familiar routes and has had two recent near misses. The patient asks whether a satisfactory brief cognitive score means driving can continue. What advice is appropriate?

A

Continue driving with no further assessment because this is a Group 1 licence

B

Use the cognitive score as the only fitness assessment

C

Allow continued driving until a serious crash occurs

D

Advise stopping driving for now, assess function and safety with appropriate support and explain NDLS notification

Sections you finish are checked off in the contents.